Biotech Values

[Summer2762]

Probably you are right.

However, prednisone in prechemo setting might be slightly more beneficial than we believe it is. Here is one trial that I'm familiar with.

http://files.shareholder.com/downloads/SNUS/2298119926x0x602114/836c4017-26fd-4180-bbfd-c25ef8ed6681/ESMO%202012%20Poster%20FINAL%20OGX427%20CRPC.pdf

The control (prednisone only) patients in that trial:
21% had >50% PSA response
41% had >5 to <5 CTC change

For post chemo, the effects seem less. In the post chemo Zytiga trial, 10% (6%) of the prednisone patients had >50% PSA (confirmed) response vs 4% (2%) for placebo in enzalutamide post chemo trial.

However, based on the info in the CC and other factors you and others identified, I think it is due to the combination of both factors and not prednisone alone.